Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jivi Post-marketing Safety and Efficacy in Hemophilia A
NCT04085458Phase 4Completed
- Sponsor
- Bayer
- Start
- Sep 2019
- Primary completion
- May 2022
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 4 trial of damoctocog alfa pegol in hemophilia A, sponsored by Bayer. Started Sep 2019; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04085458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085458.